P020 | EXTENDED LEAD-IN PHASE OF BRENTUXIMAB VEDOTIN AND SHORTENED AVD IN OLDER PATIENTS (>60 YEARS) WITH ADVANCED HODGKIN LYMPHOMA (HL) AND HIGH COMORBIDITY BURDEN (ECOG≥2 AND/OR CIRS-G>10).

Introduction: Older patients (pts) with Hodgkin Lymphoma (HL) have worse outcomes due to biological characteristics, poor performance status (PS), and comorbidities. Standard treatment may not suit many pts due to reduced tolerance, including high Doxorubicin load. We investigated whether Brentuxim...

Popoln opis

Bibliografske podrobnosti

Principais autores:	M. Bonanni, A. Cuccaro *, S. Mele *, E. Morelli, A. Fresa, M. Arcamone, F. Ibello, M. Esposito, M. Saggese, S. Crisci, M. Rivieccio, L. Simeone, F. Volzone, G. Corazzelli, R. De Filippi, A. Pinto
Format:	Artigo
Jezik:	Inglês
Izdano:	Ferrata Storti Foundation 2025-09-01
Serija:	Haematologica
Online dostop:	https://haematologica.org/article/view/12517
Oznake:	Označite Brez oznak, prvi označite!